MIODESOPSIE. LO STATO DELL’ARTE E LE PROSPETTIVE DI RICERCA. I POSSIBILI TRATTAMENTI. VITREOCTOMIA. 2. VITREOLISI LASER. 3. VITREOLISI ENZIMATICA. 4. RIMEDI ALTERNATIVI. VITREOCTOMIA. PARS PLANA VITREOCTOMIA. PARSA PLANA VITREOCTOMIA.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
LO STATO DELL’ARTE
LE PROSPETTIVE DI RICERCA
2. VITREOLISI LASER
3. VITREOLISI ENZIMATICA
4. RIMEDI ALTERNATIVI
PARS PLANA VITREOCTOMIA
STRUMENTAZIONE 25 GAUGE
OSPEDALE DI LINZ-AUSTRIA
I FLOATERS DEBILITANTI APPARTENGONO AL PASSATO
ND YAG LASER
PROTEZIONI PER LA RETINA
(cataratta, glaucoma, distacco di retina)
PRO E CONTRO
ND YAG LASER E MIODESOPSIE
Anticipation for enzymatic vitreolysis
Other applications can be envisaged. Enzymatic vitreolysis might be useful as a supplement to pneumatic retinopexy for rhegmatogenousretinal detachment repair; injecting an enzyme at the time ofgas injection to additionally release vitreous traction couldpotentially increase the success rate of this office based procedure.As another example patient complaints associated with vitreousfloaters are all too familiar to ophthalmologists, but the risk-benefitprofile for surgery for vitreous floaters is prohibitive. Couldenzymatic vitreolysis reduce risks sufficiently to become viablefor the large number of patients with this relatively benign butannoying visual problem? The arrival of enzymatic vitreolysismay expand vitreoretinal practice in ways that can't bepredicted.
Before enzymatic vitreolysis enters the mainstream central questions will need to be addressed effectiveness, inflammatoryresponses, retinal toxicity, long term complications. And yearsof work in the field of vitreolytic enzymes have yet to yielda widely accepted alternative to mechanical vitrectomy. Nevertheless,as the limits of conventional vitrectomy are being approachedvitreoretinal surgeons continue to look forward over the nextyears to a new generation of therapies with vitreolyticenzymes.
SICUREZZA ED EFFICACIA DELLA IALURONIDASI
ThromboGenics Ltd. Announces the Initiation of Phase II Trial of Microplasmin
Investigating New Drug for Treatment of Disorders of the "Back of the Eye“
ThromboGenics Ltd. today announced the start of a Phase II trial evaluating recombinant microplasmin in patients with
vitreoretinal disorders, also referred to as diseases of the "back of the eye". Microplasmin is a truncated form of the human protein plasmin; ThromboGenics has developed on a proprietary basis the first stabilized and readily manufactured form of this unique protein.
Microplasmin has the potential to simplify a surgical procedure called vitrectomy, which is used to treat visual conditions. Vitrectomy involves separation of the vitreous (the gel-like substance in the center of the eye) from the retina, inducing a posterior vitreous detachment (PVD), a technique considered beneficial in patients with numerous retinal conditions, including diabetic retinopathy and macular edema.
The breakthrough procedure using plasmin for induction of PVD was invented by Drs. Michael Trese and George Williams, the founders of NuVue Technologies, which owns exclusive rights for the use of plasmin in ophthalmic applications. A formal licensing agreement between ThromboGenics and NuVue brings into a single portfolio all intellectual property relating to plasmin-based compounds for treatment of eye diseases.
This Phase II trial, in which the first patient was treated in December 2004, will enroll up to 50 patients at 3 centers in the Netherlands and Germany. The investigators for the study are Professors Marc de Smet (Amsterdam), Arnd Gandorfer and Anselm Kampik (Munich), and Eric Feron (Rotterdam), Patients with vitreoretinal disease for whom vitrectomy is indicated will be enrolled. The trial is primarily designed to provide valuable safety information on the use of microplasmin in this setting, on which dose selection for future clinical trials can be based. Subject to interim results from this trial, ThromboGenics plans to submit an Investigational New Drug (IND) application to FDA to allow for initiation of a U.S. clinical trial with microplasmin in 2005.
FLOATERS AND THEIR TREATMENT WITH CHINESE HERBS
by Subhuti Dharmananda, Ph.D., Director, Institute for Traditional Medicine, Portland, Oregon
Am J Ophthalmol. 1956 Nov;42(5):771-2.Related Articles, Links
S Afr Med J. 1958 Mar 15;32(11):296-8.Related Articles, Links
A surgical procedure for the relief of vitreous opacities (floaters).BLUMENTHAL CJ.PMID: 13543474 [PubMed - OLDMEDLINE for Pre1966]